PPP1R16A

Chr 8

protein phosphatase 1 regulatory subunit 16A

Also known as: MYPT3

The protein functions as a myosin phosphatase targeting subunit that directs protein phosphatase 1 to specific substrates including myosin light chains, regulating muscle contraction and intracellular movement. Mutations in PPP1R16A cause autosomal recessive intellectual disability with microcephaly and seizures, typically presenting in early childhood. The gene shows moderate constraint to loss-of-function variation, suggesting some intolerance to complete protein loss.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
3
Pubs (1 yr)
55
P/LP submissions
0%
P/LP missense
0.65
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryPPP1R16A
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
55 unique Pathogenic / Likely Pathogenic· 111 VUS of 184 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.65LOEUF
pLI 0.004
Z-score 2.81
OE 0.36 (0.210.65)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.13Z-score
OE missense 0.98 (0.891.07)
320 obs / 326.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.36 (0.210.65)
00.351.4
Missense OE0.98 (0.891.07)
00.61.4
Synonymous OE1.31
01.21.6
LoF obs/exp: 8 / 22.3Missense obs/exp: 320 / 326.5Syn Z: -2.97
DN
0.7033th %ile
GOF
0.80top 10%
LOF
0.3067th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

184 submitted variants in ClinVar

Classification Summary

Pathogenic50
Likely Pathogenic5
VUS111
Likely Benign9
Benign2
50
Pathogenic
5
Likely Pathogenic
111
VUS
9
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
50
0
50
Likely Pathogenic
0
0
5
0
5
VUS
0
97
14
0
111
Likely Benign
0
6
1
2
9
Benign
0
0
2
0
2
Total0103722177

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PPP1R16A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →